Mark G. Kris, MD
Dr. Kris is a specialist in lung cancers with particular interest in developing strategies to choose treatments for patients based on molecular characteristics of the tumor specimens. He has authored and coauthored more than 280 original scientific publications. His research includes the evaluation of new anticancer agents and multimodality therapy to improve outcomes for individuals with thoracic cancers, and the training of the IBM Watson cognitive computer system to assist physicians in choosing the best treatments for their patients.
A fellow of the American College of Physicians, the American College of Chest Physicians, and the American Society of Clinical Oncology (ASCO), Dr. Kris is also a member of the American Association for Cancer Research and the International Association for the Study of Lung Cancer, and a member of the guideline panels on non–small cell lung cancers and antiemetics for the National Comprehensive Cancer Center Network. Additionally, he serves on the ASCO Antiemetic Guideline Panel and previously was co-chair on for ASCO’s Guideline Panel for Adjuvant Chemotherapy and Radiation for Non–Small Cell Lung Cancers. Dr. Kris received his Doctor of Medicine degree from Weill Cornell Medical College.
Mark G. Kris, MD, reported a financial interest/relationship or affiliation in the form of: advisory board, AstraZeneca Pharmaceuticals LP, Clovis Oncology; contracted research, Pfizer, Inc., PUMA Biotechnology.
Roy S. Herbst, MD, PhD
Dr. Roy S. Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut. He has led the phase 1 development of several of the new generation of targeted agents for non–small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. In addition, he is colead for the BATTLE-1 effort, coleads the subsequent BATTLE-2 clinical trial program, and serves as a co-program leader of the Developmental Therapeutics Program for the Yale Cancer Center Support Grant. Dr. Herbst is a member of the National Cancer Policy Forum for which he has organized an Institutes of Medicine meeting focused on policy issues in personalized medicine. His laboratory work is focused on angiogenesis and dual epidermal growth factor receptor/vascular endothelial growth factor receptor inhibition in NSCLC. This work has been translated from the preclinical to clinical setting in multiple phase 2 and 3 studies that he has led. Dr. Herbst has authored and coauthored more than 250 publications, including peer-reviewed journal articles, abstracts, and book chapters. Dr. Herbst is an active member of the American Society for Clinical Oncology, the American Association for Cancer Research, the International Association for the Study of Lung Cancer, the Radiation Therapy Oncology Group, and the Southwest Oncology Group Lung Committee. He earned is Doctor of Medicine degree from Cornell University Medical College in New York, New York.
Roy S. Herbst, MD, PhD, reported a financial interest/relationship or affiliation in the form of: scientific advisory board, Biothera, Diatech Oncology, Kolltan Pharmaceuticals, Inc., N-of-One, NovaRx Corporation, Quintiles; consultant, Boehringer Ingelheim, Eli Lilly and Company, Genentech - A member of the Roche Group, Merck & Co., Inc., Pfizer, Inc., Synta Pharmaceuticals Corp.; clinical trial support/grant, Genentech, Inc.
Dr. Karen L. Reckamp is Co-Director of the Lung Cancer and Thoracic Oncology Program and Associate Professor, Medical Oncology & Therapeutics Research at City of Hope in Duarte, California. She has expertise in targeted therapies and inflammation in lung cancer with an emphasis on cyclooxygenase-2 and collaborates with colleagues in the design, conduct, and enrollment of clinical trials through her efforts in multidisciplinary clinics, tumor boards, and research conferences. Dr. Reckamp has been responsible for protocol development, Institutional Review Board submission, informed consent issues, planning subject recruitment and retention, managing adverse events, data collection management, and Investigational New Drug preparation and submission to the US Food and Drug Administration for multiple phase 1, 2, and 3 trials at City of Hope.
Dr. Reckamp has been the recipient of many honors including the Clinical Investigator Award from Phase One Foundation in 2006. She has also authored or coauthored many manuscripts in the field of thoracic oncology. Dr. Reckamp received her Doctor of Medicine degree from the University of Chicago, Pritzker School of Medicine and also completed a Master of Science in Clinical Investigation at the University of California, Los Angeles.
Karen L. Reckamp, MD, MS, reported a financial interest/relationship or affiliation in the form of: advisory board, Amgen, Inc., Boehringer-Ingelheim, Bristol-Myers Squibb Company; Contracted Research, Amgen, Inc., Ariad Pharmaceuticals, Inc., Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation.
Lecia V. Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Chair of the Clinical Trials Committee for Thoracic Oncology
Dana-Farber/Harvard Cancer Center
Attending Physician, Medicine
Massachusetts General Hospital
Dr. Lecia Sequist is currently Associate Professor of Medicine at Harvard Medical School and Chair of the Clinical Trials Committee for Thoracic Oncology at the Dana Farber/Harvard Cancer Center in Boston, Massachusetts. She leads clinical and translational research efforts through grants from the National Institutes of Health, the Department of Defense, and private foundations, and also directs a busy practice caring for patients with lung cancer. Her research focuses on studying novel targets for lung cancer treatment, especially in patients with epidermal growth factor receptor mutations and other driver oncogenes. Dr. Seaquist also studies the changes that occur in cancers at the time of acquired drug resistance and the significance of tumor cells circulating in the bloodstream. Her aim is to develop treatment algorithms for lung cancer that are more personalized than current strategies, using targeted therapies specific to the patients’ cancer genotypes, and understanding how this may change over the course of the disease.
A graduate of the prestigious American Society of Clinical Oncology Leadership Development program, Dr. Seaquist received her Doctor of Medicine degree from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received a Master of Public Health degree from the Harvard School of Public Health.
Lecia V. Sequist, MD, MPH, reported a financial interest/relationship or affiliation in the form of: uncompensated consulting relationship, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Clovis Oncology, Genentech, Inc., Merrimack Pharmaceuticals, Novartis Pharmaceuticals Corporation, Taiho Pharmaceutical Co., Ltd.
Mark A. Socinski, MD
Dr. Mark A. Socinski is Professor of Medicine and Thoracic Surgery and Director of the Lung Cancer Section, Division of Hematology/Oncology at the University of Pittsburgh in Pittsburgh, Pennsylvania. Board-certified in internal medicine and medical oncology, he is also Co-Director of the UPMC Lung Cancer Center of Excellence and the Lung and Thoracic Malignancies Program and the Clinical Associate Director of the Specialized Program of Research Excellence in Lung Cancer at the University of Pittsburgh Medical Center. Dr. Socinski is a member of several professional organizations including the American College of Physicians, the American Society of Clinical Oncology, Cancer and Leukemia Group B, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He has authored many manuscripts in the field of thoracic oncology.
Dr. Socinski received his Master of Science degree in Pathology and his Doctor of Medicine degree from the University of Vermont in Burlington. He completed an internal medicine internship and residency at Harvard Medical School Beth Israel Hospital in Boston, Massachusetts, and subsequently completed medical oncology and clinical medicine fellowships at the Dana-Farber Cancer Institute, Harvard Medical School.
Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form of: speakers’ bureau, Celgene Corporation, Genentech, Inc.; contracted research, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., Lilly USA, Peregrine Pharmaceuticals, Inc., Pfizer, Inc., Synta Pharmaceuticals Corp.